The reiteration of a Buy rating and a high price target of $105 by a reputable analyst firm like HC Wainwright & Co. suggests a strong bullish outlook for Praxis Precision Medicine. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in PRAX's stock price, given the high relevance and importance of analyst ratings in guiding investor decisions.